12:00 AM
Nov 25, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aldoxorubicin: Phase II started

CytRx began an open-label, U.S. Phase II trial to evaluate 250 and 350 mg/m 2 IV aldoxorubicin every 21 days in up to 28 patients with unresectable GBM who progressed following surgery, radiation and temozolomide....

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >